Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
10/02/2014 > 228 patent applications in 175 patent subcategories.

20140296128 - Materials and methods for treatment of cancer and identification of anti-cancer compounds: The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns... Agent: University Of South Florida

20140296129 - Regulation of receptor expression through delivery of artificial transcription factors: The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a receptor gene promoter fused to an inhibitory or activatory protein domain, a nuclear localization sequence, and a protein transduction domain. In particular examples these receptor gene promoters regulate the expression of the endothelin... Agent:

20140296130 - Novel inhibitors of mammalian tight junction opening: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition... Agent:

20140296131 - Truncated glp-1 derivatives and their therapeutical use: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position... Agent: Novo Nordisk A/s

20140296132 - Anti-bacterial polypeptides and pathogen specific synthetic antibodies: The present invention provides polypeptides, compositions thereof, and methods for use of the polypeptides in treating bacterial infection and for use as disinfectants.... Agent: Arizona Board Of Regents Of Behalf Of Arizona State University

20140296134 - Methods and uses for metabolic profiling for clostridium difficile infection: Embodiments include methods for generating a metabolite profile of a stool sample and methods of assessing the status of a subject using the metabolic profile derived from a stool sample.... Agent: The Board Of Regents Of The University Of Texas System

20140296133 - Sila analogs of oxazolidinone derivatives and synthesis thereof: The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation... Agent: Council Of Scientific & Industrial Research

20140296135 - Medicament for the treatment of fungal infections particularly aspergillosis: The combination of pentraxin PTX3 with antifungals is described for the treatment of fungal infections and particularly for infections caused by Aspergillus fumigatus.... Agent:

20140296136 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent:

20140296138 - Methods and compositions for controlling nematode pests: Transgenic plants expressing a Vip3 protein have been found to be efficacious against plant-infesting nematodes. Disclosed are methods of controlling nematode populations using transgenic plants expressing Vip3 protein.... Agent: Syngenta Participations Ag

20140296137 - Methods and compositions for controlling rotifers: Described herein are compositions and methods for controlling, inhibiting, reducing and/or preventing rotifer growth with antimicrobial peptides. Methods for removing and/or preventing rotifer infestations in algae cultivations by controlling, inhibiting, reducing and/or preventing rotifer growth with an antimicrobial peptide (AMP) are further provided. Also described are transgenic algae comprising an... Agent:

20140296139 - Mitochondrial-derived peptide mots3 regulates metabolism and cell survival: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.... Agent:

20140296140 - Equipment assembly for and method of processing particles: An equipment assembly for preparing, harvesting and collecting particles is disclosed. The assembly comprises a tandem filter system with one or more high pressure filters, one or more low pressure filters and one or more collection vessel. Particles can be prepared, harvested and collected continuously, semi-continuously or in a batch-type... Agent: Crititech, Inc.

20140296141 - Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus: The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein... Agent: New York Univeristy

20140296142 - Gene therapy for diabetic neuropathy using an hgf isoform: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented... Agent: Viromed Co., Ltd

20140296143 - Angiotensin-(1-7) as a chemoprevention agent: Disclosed is the use of angiotensin-(1-7) peptide as an anti-cancer and chemoprevention therapeutic. Embodiments of the present invention comprise methods and compositions to prevent cancer or to reduce the risk of cancer in an individual comprising administering to the individual a pharmaceutically effective amount of an agonist for the angiotensin-(1-7)... Agent:

20140296144 - Process for the preparation of octreotide acetate: The present invention relates to an improved process for large scale production of Octreotide acetate. The invention also relates to pharmaceutical composition of octreotide acetate.... Agent:

20140296145 - Modified human growth hormone polypeptides and their uses: Modified human growth hormone polypeptides and uses thereof are provided.... Agent: Ambrx, Inc.

20140296146 - Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces: The present invention relates to the field of blood clotting. Specifically, the invention relates to particular inhibitors of artificial activation of the blood clotting process through contact with foreign surfaces.... Agent: Universiteit Maastricht

20140296147 - Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010: Methods of inhibiting, treating or preventing blood loss in a subject undergoing surgery through the administration of an effective amount of the novel serine protease inhibitor MDCO-2010 or its salts or esters are disclosed.... Agent:

20140296148 - Medicament for therapeutic treatment and/or improvement of sepsis: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.... Agent:

20140296149 - Compositions and methods for the treatment of cardiac surgery-associated acute kidney injury with annexin a1 peptide: The present invention provides a method of treating, ameliorating and/or preventing cardiac surgery-associated acute kidney injury (AKI) in a subject, comprising administering to the subject a therapeutically effective amount of an ANXA1 peptide such that the AKI is treated, ameliorated and/or prevented.... Agent:

20140296150 - Carrier-linked treprostinil prodrugs: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).... Agent: Ascendis Pharma A/s

20140296151 - Peptides from fish gelatine: The invention relates to a process of preparing low molecular weight peptides from gelatine. The gelatine is broken down into low molecular weight peptides using enzymes from Bacillus sp. to obtain peptides with low ash content. The gelatine is clarified by adjusting the pH to 7 using alkali hydroxide and... Agent:

20140296152 - Stem cell derived factors for treating pathologic conditions: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.... Agent: The Brigham And Women's Hospital, Inc.

20140296153 - Oligodendrocyte differentiation: The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the loss of the myelin sheath that insulates the nerves) is an associated or causative feature. The data provided demonstrate the... Agent:

20140296154 - Method of preventing development of psoriatic lesions: The present invention relates to a method of inhibiting onset of or preventing development of a psoriatic lesion in a patient having psoriasis. The method comprises administering to a patient having psoriasis an effective amount of an agent that inhibits NF-κB activity under conditions effective to inhibit onset of or... Agent: University Of Rochester

20140296155 - Anti-stretch mark skin cream and method for making and using thereof: A skin cream and method for making and applying the skin cream having, e.g., a copper component, an ascorbic acid component, a lipid component and a peptide component. The peptide component can include palmitoyl pentapeptide (KTTLS) or hydrolized serecin. The copper component can be a copper solubilizing formulation. The copper... Agent:

20140296156 - Peptide based inhibition of capcna interaction in cancer: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also... Agent:

20140296157 - Compositions and methods for preparing a subject for organ or non-organ implantation: Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantion rejection in the subject. Other embodiments include treating a subject with a composition... Agent: The Regents Of The University Of Colorado, A Body Corporate

20140296158 - Sustained action formulation of cyclosporin form 2: Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.... Agent:

20140296159 - Method for therapeutic replenishment and enrichment of ocular surface lubrication: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant... Agent:

20140296161 - Didemnin biosynthetic gene cluster in tistrella mobilis: A novel Tistrella mobilis strain having Accession Deposit Number NRRL B-50531 is provided. A method of producing a didemnin precursor, didemnin or didemnin derivative by using the Tistrella mobilis strain, and the therapeutic composition comprising at least one didemnin or didemnin derivative produced from the strain or modified strain thereof... Agent: King Abdullah University Of Science And Technology

20140296160 - Stabilized alpha helical peptides and uses thereof: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive... Agent: Dana-farber Cancer Institute, Inc.

20140296162 - Whey protein composition with a reduced astringency: The invention relates to a sterilized liquid or semi-solid acid enteral composition comprising per 100 ml 9 to 20 g of non-hydrolysed globular proteins, fat and at least 100 mg of divalent metal cations and having a pH ranging between 3 and 5. The invention further relates to a method... Agent: N.v. Nutricia

20140296163 - Methods and compositions for the treatment of gastrointestinal disorders: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and... Agent: Ironwood Pharmaceuticals, Inc.

20140296164 - Compositions and methods of use for cell targeted inhibitors of the cystic fibrosis transmembrane regulator associated ligand: The present invention describes peptide drugs that inhibit the interaction between CAL and CFTR, and other proteins in cystic fibrosis and other diseases. These invented drugs have been chemically optimized to impart solubility, stability, cell permeability, mucus penetration, intracellular targeting and sequestration, increased potency and non-immunogenicity, while conserving and imparting... Agent: Calista Therapeutics, Inc.

20140296165 - Use of tight junction antagonists to treat inflammatory bowel disease: The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject... Agent:

20140296166 - Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction: The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analogue or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart... Agent:

20140296167 - Glycosylation site-specific antibodies and anti-cancer compounds: A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening... Agent:

20140296169 - Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals: in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore... Agent:

20140296168 - Mixture composition comprising rhamnolipids: The invention relates to a mixture composition comprising rhamnolipids, to a process for its preparation, to its use for producing formulations and to formulations comprising this mixture composition.... Agent: Evonik Industries Ag

20140296170 - Pharmaceutical composition for prevention or treatment of bone diseases comprising spinasterol glucoside derivative: Disclosed is a pharmaceutical composition for the prevention or treatment of metabolic bone diseases, comprising a spinasterol glucoside derivative, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The pharmaceutical composition is effectively useful for preventing or treating metabolic bone diseases.... Agent: Lifetree Biotech Co., Ltd.

20140296171 - Novel urea compounds: s

20140296172 - Method for screening compounds comprising the use of picornavirus protease 2a: A method of screening compounds or molecules comprising the steps of: translating a sequence encoding the amino acid sequence comprising SEQ ID No. 29 in a translation system in the presence of a test compound or molecule; and analysing the translation product(s) for the presence of one or more of... Agent: University College Cork - National University Of Ireland, Cork

20140296174 - Silk-based multifunctional biomedical platform: The present invention provides a multifunctional platform suitable for biomedical applications. In particular, the invention includes a silk fibroin-based multifunctional device that enables both the sustained delivery of a drug and monitoring of such delivery in vivo.... Agent:

20140296173 - Stable nanocomposition comprising epirubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it: A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked... Agent: Bbs Nanotechnology LLC.

20140296175 - Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell: A composition for inducing erythropoietin (EPO)-mediated haemoglobin (Hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (I), wherein R is a glycosyl group; and a pharmaceutical acceptable carrier.... Agent: National Yang-ming University

20140296319 - Composition for promoting apoptosis or inhibiting cell growth, comprising epstein-barr virus microrna: Provided is a use of an miRNA of an Epstein-Barr virus (EBV), more specifically, EBV miR-BART4-5p, miR-BART4-3p, miR-BART1-5p, miR-BART15-3p, miR-BART5-5p, miR-BART5-3p, miR-BART16-5p, miR-BART16-3p, miR-BART17-3p, miR-BART21-3p, miR-BART18-5p, miR-BART7-5p, miR-BART9-5p, miR-BART22-5p, miR-BART20-3p, miR-BART13-5p, miR-BART13-3p, miR-BART2-3p, and mimics thereof for promoting apoptosis or inhibiting cell growth.... Agent: Catholic University Industry Academic Cooperation Foundation

20140296322 - Conjugates, particles, compositions, and related methods of use: Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.... Agent: Cerulean Pharma Inc.

20140296321 - Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites: Provided herein are antisense oligonucleotides, compositions comprising antisense oligonucleotides, and methods for the use of antisense oligonucleotides in manipulating translation. Expression of isoforms of proteins expressed from different start codons of the same transcript are inhibited by antisense oligonucleotides, which may also enhance expression of non-target isoforms.... Agent: Sarepta Therapeutics, Inc.

20140296318 - Novel tissue protective erythropoietin receptor (nepor) and methods of use: Methods of determining whether a patient is suitable for erythropoietin (EPO) therapy, including (A) isolating a tissue sample from said patient; (B) determining the level of expression of EPH-B4 in said sample; and (C) correlating a presence of EPH-B4 expression to a negative physiological response to EPO therapy). In addition,... Agent: Molecular Health Gmbh

20140296323 - Tricyclo-phosphorothioate dna: The present invention relates to a nucleic acid molecule containing a sequence of tricyclo nucleosides joined by internucleoside phosphorothioate linkage. The invention also relates to synthetic antisense oligonucleotides and to methods employing the same.... Agent:

20140296320 - Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide: The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression... Agent: Senesco Technologies, Inc.

20140296327 - Diagnosis and treatment of mesothelioma: This disclosure provides methods for surveillance, early detection and diagnosis, subtype classification, prediction of recurrence, prognosis and therapy of malignant mesothelioma based on profiles of indicator mutations in disclosed genes.... Agent: The Brigham And Women's Hospital, Inc.

20140296326 - Epidermal growth factor receptor (egfr) and methods of use in adenoviral-associated virus type 6 (aav6) transduction: Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of... Agent:

20140296325 - Methods and compositions for inducing brown adipogenesis: Methods and compositions for treating obesity and related disorders. The methods include the use of stem cells treated with BMP-2, -4, -5, -6 and/or -7.... Agent: Joslin Diabetes Center, Inc.

20140296324 - Vectors harboring toxic genes, methods and uses therefor: The present disclosure describes nucleic acids, and viruses comprising such nucleic acids, for growing a toxic gene in an insect cell. These nucleic acids comprise a sequence encoding a toxic polypeptide, and an intron that interrupts the sequence, whereby the intron is spliced in mammalian cells but not in insect... Agent: Virovek Incorporation

20140296176 - Combination cancer therapy with an hsp90 inhibitor and an antimetabolite: The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formulae (I) 40 or (Ia) in combination with an antimetabolite such... Agent: Synta Pharmaceuticals Corp.

20140296177 - Novel antimicrobial compounds: A new class of biotin protein ligase (BPL) inhibitors that have antibacterial activity against multiple Staphylococcus aureus isolates, including clinically important methicillin-resistant S. aureus (MRSA) are disclosed that are non-toxic.... Agent:

20140296178 - Combination therapy with a gallium complex: A combination therapy is disclosed for treating cancer. The method comprises identifying a patient diagnosed of cancer and in need of treatment, administering to a cancer patient a therapeutically effective amount of a compound of Formula (I), and administering to said patient a therapeutically effective amount of a certain second... Agent: Niiki Pharma Acquisition Corp. 2

20140296179 - Nutritional composition comprising immunoglobulins and oligosaccharides: The present invention provides a method and composition for the treatment and/or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and immunoglobulin from the milk or colostrum of hyperimmunized cows.... Agent: N.v. Nutricia

20140296180 - Cyclic oligosaccharides for use in the treatment and prevention of bacterial infection: Compounds which inhibit Wza-mcdiated polysaccharide transport are useful in the prevention or treatment of bacterial infection, in particular of E. coli infection. The compounds are typically cyclic oligosaccharides such as cyclodextrins, which bear positively charged functional groups at the primary carbon position.... Agent: Isis Innovation Limited

20140296183 - Amine compound and use thereof for medical purposes: wherein R is a hydrogen atom or P(═O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH═CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1... Agent:

20140296182 - Method and composition for treating lice infestation: Methods and compositions for the treatment of pediculosis comprising: between 1 and 20% (w/w) isopropyl myristate; between 1 and 20% (w/w) silicone oil; and at least 20% (w/w) water. Methods and compositions for dissolving nit glue comprising at least three components selected from the group consisting of benzyl alcohol, diacetone... Agent:

20140296181 - Methods of modulating oncogenic fusion proteins: Described herein, at least in part, are methods of modulating oncogenic fusion proteins.... Agent: Coferon, Inc.

20140296184 - Silylated azulenyl nitrone spin traps as chromotropic superoxide detectors: Silylated nitrones and methods of detecting and/or superoxide using silylated nitrones are disclosed herein.... Agent:

20140296185 - Solid formulations suitable for oilfield applications: l

20140296186 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising... Agent:

20140296187 - Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof: A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to... Agent:

20140296188 - New therapy for transthyretin-associated amyloidosis: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid,... Agent:

20140296189 - Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine: A method of reducing niacin flushing in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.... Agent: Theaprin Pharmaceuticals Inc.

20140296191 - Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as... Agent: Themis Medicare Limited

20140296190 - Marketing the use of 25-hydroxyvitamin d3 to enhance cognition: This invention relates to a method of marketing 25-hydroxyvitamin D3 (25-OH D3) comprising providing an effective dose of 25-OH D3 and informing the potential consumer that it is beneficial for increasing or maintaining executive functioning, or lessening the decrease of cognitive functioning. Kits containing the 25-OH D3 and information regarding... Agent: DsmIPAssets B.v.

20140296193 - Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen: A method of contraception in a female is provided. The method includes administering to the female daily for a first number of successive days an oral combination drug formulation of a progestin and an estrogen. The oral combination drug formulation is administered in a multiphasic dosing regimen comprising a second... Agent: Arstat, Inc.

20140296192 - Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid: The invention relates to a pharmaceutical composition of unit dose for inhalation by a human subject comprising a topical corticoid and a quinolone or fucidic acid, characterized in that the ratio of the weight of the topical corticoid to the weight of the quinolone or fucidic acid is between 0.02... Agent: Antonio Dos Santos

20140296194 - Prevention or attenuation of neuropathic pain and kidney injury by tauroursodeoxycholic acid: Methods of reducing or abolishing neuropathic pain in humans and animals are discussed. In some examples administration of the apoptosis inhibitor taurours-odeoxycholic acid (TUDCA), greatly reduced both neuronal loss and the increase in glia, and partially reversed spinal nerve ligation (SNL)-induced mechanical hypersensitivity. Among RVM neurons, serotonergic (5-HT) neurons decreased... Agent:

20140296197 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists: Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma... Agent:

20140296195 - Method for the treatment of central nervous system cancers and compositions related thereto: Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with,... Agent:

20140296196 - Nk1 antagonists: e

20140296198 - Assay for predictive biomarkers of anti-estrogen efficacy: Biomarkers associated with anti-estrogen sensitivity in cancers, methods for detecting and quantitating the biomarkers, and methods for treating cancer patients that exhibit the biomarkers are provided. The biomarkers are activated estrogen receptor foci (AEF) found in the nuclei of certain tumor cells. The methods provide new information to guide the... Agent: Invivis Sas A Corporation

20140296199 - Pharmaceutical delivery systems for hydrophobic drugs and compositions compositions comprising same: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also... Agent:

20140296200 - 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide inhibitors of phd: d

20140296204 - Chemical compounds: The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of... Agent:

20140296201 - Inhibitors of influenza viruses replication: or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of... Agent:

20140296203 - Novel compounds that are erk inhibitors: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).... Agent:

20140296202 - Substituted piperidinyl compounds useful as gpr119 agonists: Substituted piperidinyl compounds of the formula (I): are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.... Agent: Merck Sharp & Dohme Corp.

20140296206 - Compositions useful for treating disorders related to kit: Compounds and compositions useful for treating disorders related to Kit are described herein.... Agent: Blueprint Medicines Corporation

20140296207 - Heterocyclic compounds and uses thereof: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.... Agent:

20140296205 - Selective glycosidase inhibitors and uses thereof: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.... Agent: Alectos Therapeutics Inc.

20140296208 - Kinase inhibitors: wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of... Agent: Respivert Limited

20140296209 - Compounds and methods for treatment of hypertension: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B—The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease... Agent: Medivation Technologies, Inc.

20140296210 - Pharmacological treatment of cognitive impairment: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a noncompetitive GABAA ionophore blocker is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140296211 - Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection: This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.... Agent: Anavex Life Sciences Corp.

20140296212 - Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands: i

20140296213 - New polymorph: The invention provides a new polymorph of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzyl-carbamoyl)-L-proline-N,N-dimethylamide, pharmaceutical compositions containing it and its use in therapy.... Agent: Vantia Limited

20140296215 - Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof: The present disclosure provides pharmaceutical compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The pharmaceutical compositions, pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The pharmaceutical compositions and... Agent: The Regents Of The University Of California

20140296217 - Medicaments for the treatment or prevention of fibrotic diseases: e

20140296216 - Pyrimido[4,5-d]pyrimidinyl compounds, pharmaceutical compositions and uses thereof: A compound of formula (I) or (II) and use of the compound in the preparation of drugs for treating cancer are disclosed. The study shows that the compounds can inhibit the growth of many kinds of tumor cells, can be used for targeting epidermal growth factor receptor (EGFR), and particularly... Agent: Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

20140296214 - Substituted tetrahydroisoquinoline compounds as factor xia inhibitors: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.... Agent:

20140296219 - Compounds for modulating tlr2: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-κB activation to treat viral infections and inflammatory conditions.... Agent: University Of Massachusetts

20140296218 - Super-enhancers and methods of use thereof: The present invention relates in some aspects to super-enhancers and related compositions, methods, and agents that are useful for modulating expression of cell type-specific genes that are required for maintenance of cell identity (e.g., embryonic stem cell identity) or maintenance of a disease state (e.g., cancer).... Agent: Whitehead Institute For Biomedical Research

20140296220 - Pyridazino[4,5-d]pyrimidin-5(6h)-one inhibitors of kinases: e

20140296221 - Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use: and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-, -L2-, and -L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been... Agent: Merck Sharp & Dohme Corp.

20140296222 - Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use: and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-, -L2-, and -L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been... Agent: Merck Sharp & Dohme Corp.

20140296223 - Method for regulating skin pigmentation: This invention relates to a method for regulating skin pigmentation of a subject, comprising the step of administering the agent for inhibiting the expression or activation of Microphthalmia Transcription Factor (MITF) to the subject who is in need of regulation of skin pigmentation.... Agent: The General Hospital Corporation

20140296225 - Inhibitors of the renal outer medullary potassium channel: i

20140296224 - Quinoline derivatives as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent:

20140296226 - Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, L,... Agent:

20140296227 - Apoptosis inducing compounds: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and R5 are independently selected from the group comprising, inter aliae, H, optionally substituted, branched or linear C1-C12 alkyl, halogen atom and C1-C12 haloalkyl, and wherein A represents a single bond or an optionally substituted C1-C6... Agent:

20140296229 - Indolinone analogues: e

20140296228 - Inhibitors of human immunodeficiency virus replication:

20140296230 - Dihydroquinazolinone analogues: wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a... Agent: Boehringer Ingelheim International Gmbh

20140296231 - Amino-substituted imidazopyridazines: The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R3 and n are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical... Agent: Bayer Intellectual Property Gmbh

20140296232 - Compounds for the treatment of mycobacterial infections: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:... Agent: The Broad Institute, Inc.

20140296233 - Heteroaryl compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Celgene Avilomics Research, Inc.

20140296234 - Pyrimidine derivatives as mtor inhibitors: wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation... Agent: Cellzome Limited

20140296235 - 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors: e

20140296236 - Quinolines as fgfr kinase modulators: The invention relates to new quinoline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. Formula (I)... Agent: Astex Therapeutics Limited

20140296237 - Picolinamide derivatives as ttx-s blockers: The present invention relates to picolinamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these... Agent:

20140296238 - Dihydropyrazoles: e

20140296239 - Biaryl-propionic acid derivatives and their use as pharmaceuticals: wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal... Agent: Sanofi

20140296240 - Substituted aminopropionic derivatives as neprilysin inhibitors: e

20140296241 - The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by... Agent:

20140296242 - Compounds for treating cancer, for administering, and for pharmaceutical compositions: Some embodiments of this invention include methods for treating disease and methods for administering a compound of the invention. In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of the invention. Pharmaceutical compositions of some embodiments of the present invention comprise a... Agent: University Of Louisville Research Foundation, Inc.

20140296243 - Bromodomain inhibitors and uses thereof: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Agent: Constellation Pharmaceuticals, Inc.

20140296244 - Method for treating a pulmonary hypertension condition: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.... Agent:

20140296245 - Benzenesulfonamide compounds and their use as therapeutic agents: This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.... Agent:

20140296246 - Benzimidazolone derivatives as bromodomain inhibitors: i

20140296247 - Heterocyclic compounds and uses thereof in the treatment of sexual disorders: Biologically active compounds, which are useful for treating a sexual disorder, are provided herein. Further provided are pharmaceutical compositions formulated for transdermal composition, which comprise a biologically active compound useful for treating a sexual disorder. The compounds and pharmaceutical compositions allow for a prolonged presence of a biologically active compound... Agent: Atir Holding S.a.

20140296248 - Methods and compositions for predicting resistance to anticancer treatment: The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a lung cancer patient, wherein a reduced expression of a MEDIATOR and/or SW1/SNF... Agent: Stichting Het Nederlands Kanker Instiuut-antoni Van Leeuwenhoek Ziekenhuis

20140296249 - 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use: Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved D3 receptor affinity and selectivity, as well as water solubility, is achieved.... Agent: The University Of North Texas Health Science At Fort Worth

20140296250 - Trazodone and trazodone hydrochloride in purified form: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of... Agent: Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

20140296251 - Multifunctional quinoline derivatives as anti-neurodegenerative agents: Novel quinoline derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases.... Agent: Annji Pharmaceutical Co., Ltd.

20140296252 - 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities: v

20140296253 - Diphenylmethyl piperazine derivative and pharmaceutical composition using same: (In the formula, R1 is a hydrogen atom or a hydroxy group. R2 is a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group having one to five carbon atoms, or an alkoxyl group having one to five carbon atoms, excluding the case where R1 is a hydroxy... Agent: Aetas Pharma Co., Ltd.

20140296254 - Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.... Agent: Galderma Research & Development

20140296255 - Lysine demethylase inhibitors for thrombosis and cardiovascular diseases: The invention relates to methods and compositions for the treatment or prevention of thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event. In particular, the invention relates to an LSD inhibitor such as a 2-cyclylcyclopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use... Agent: Oryzong Genomics, S.a.

20140296256 - Plasminogen activator inhibitor-1 inhibitor: The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various... Agent:

20140296257 - High-loading water-soluable carrier-linked prodrugs: The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is... Agent: Ascendis Pharma A/s

20140296258 - Trisubstituted triazolopyrimidines for use in platelet aggregation inhibiton: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.... Agent: Astrazeneca Uk Limited

20140296259 - 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances: or pharmaceutically acceptable salts or propharmacons thereof, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH, which has a Hammett constant σp greater than 0.23. The present invention also concerns the method of its manufacture. For... Agent:

20140296260 - 3-aryl-2-((arylamino)methyl)quinazolin-4-(3h)-ones: The invention relates to novel quinazolinone compounds and their use as inhibitors of PI3 kinases, for example, PI3Kδ, for treating and/or preventing diseases, disorder, and conditions associated with modulating PI3 kinase activity. Novel 3-aryl-2-((arylamino)methyl)quinazolin-4(3H)-one derivatives and pharmaceutically acceptable salts or solvates thereof and their use for the treatment or prevention... Agent:

20140296261 - Kinase modulating compounds, compositions containing the same and use thereof: The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.... Agent: Chia Tai Tianqing Pharmaceutical Group Co., Ltd,

20140296262 - Method to treat premature ejaculation in humans: The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides methods and compositions for treating sexual dysfunction; more particularly, the invention relates to treatment of premature ejaculation in humans.... Agent: Trinity Laboratories, Inc.

20140296263 - Substituted xanthine derivatives: The present invention in one embodiment relates to a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein: each of R1 and R2 is independently selected from —CH3 and —CD3; R3 is hydrogen or deuterium; each of Z1, Z2 and Z3 is independently selected from hydrogen and deuterium;... Agent: Concert Pharmaceuticals, Inc.

20140296264 - Mgmt inhibitor combinations for the treatment of neoplastic disorders: A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.... Agent:

20140296265 - Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor: The invention provides a method for treating cancers including hematologic malignancies comprising administering a compound of formula I:... Agent: Exelixis, Inc.

20140296267 - Solid dispersions of a erb2 (her2) inhibitor: A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.... Agent:

20140296266 - Therapeutic compounds: s

20140296268 - Therapeutic methods and compositions involving allosteric kinase inhibition: The present invention is directed to methods and compositions for suppressing lymphangiogenesis, angiogenesis and/or tumor growth. The methods comprise contacting the tumor with a compound that (i) stabilizes a protein kinase in the inactive state and (ii) is not an ATP competitive inhibitor of the protein kinase in the active... Agent:

20140296269 - Composition and method for controlling plant diseases: The present invention provides a composition for controlling plant diseases having an excellent control efficacy on plant diseases. A composition for controlling plant diseases comprising an amide compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at... Agent: Sumitomo Chemical Company, Limited

20140296270 - Stat3 inhibitors: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well... Agent: Baylor College Of Medicine

20140296271 - Kinase inhibitor: which compound has antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases, e.g., Src and Lck) and has use in therapy, including in pharmaceutical combinations, especially in the... Agent: Respivert Limited

20140296272 - Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors: The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention... Agent:

20140296273 - Method and compositions for treatment or prevention of inflammatory conditions: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin... Agent:

20140296275 - Combinations of an opioid/tlr4 antagonist and an alpha-2-delta ligand for use in the treatment of pain: Disclosed are compositions for treatment of pain comprising, a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor (TLR4) and the second compound is an alpha-2-delta ligand that enhances the pain treatment effect of the first compound. Examples of... Agent:

20140296277 - Pharmaceutical preparation containing oxycodone and naloxone: The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.... Agent:

20140296276 - Sequestered antagonist formulations: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the... Agent: Purdue Pharma L.p.

20140296274 - Treatment of pain using a composition of opioid/toll-like receptor 4 antagonists and dextro enantiomers thereof: This invention relates to the use of a composition comprising opioid/Toll-like receptor 4 (TLR4) antagonists and dextro enantiomers thereof for the treatment of pain, where the opioid antagonists treat pain by blocking TLR4. More preferably, the dextro opioid/TLR4 antagonist enantiomer treats pain by blocking TLR4 while not affecting the opioid... Agent:

20140296278 - 5-nonyloxytryptamine and related intracellular ph acidifiers for the treatment and prevention of cancer: Provided herein are compositions for lowering intracellular pH in a cell or population of cells from a subject comprising contacting the cell or population of cells with a therapeutically effective amount of 5-nonyloxytryptamine or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivatives thereof. These compounds are useful for acidification of... Agent:

20140296279 - Intravascular delivery of nanoparticle compositions and uses thereof: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in... Agent: Abraxis Bioscience, LLC

20140296280 - Pures-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1h,-5h-benzo[i,j]quinolizine-2- carboxylic acid l-arginine salt tetrahydrate and a process for its preparation: Pure S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,-5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt tetrahydrate and a process for its preparation is disclosed.... Agent:

20140296281 - Methods for screening a brca1 loss-of-function in a subject suffering from a cancer: The present invention relates to a method for screening a BRCA1 loss-of-function in a subject comprising the step consisting of determining the level of serine 211 phosphorylated glucocorticoid receptor (GR P-Ser211) expression in a tissue sample obtained from said subject.... Agent:

20140296282 - Compositions of a polyorthoester and an aprotic solvent: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release.... Agent: Heron Therapeutics, Inc.

20140296283 - Substituted 6,5-fused bicyclic heteroaryl compounds: The present invention relates to azole bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research... Agent: Epizyme, Inc.

20140296284 - Crystalline forms of kinase inhibitors: Citrate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.... Agent:

20140296285 - Preparation and application of the new antibacterial and anticancer compounds and their derivatives: t

20140296286 - Compounds with increased specificity for the treatment of glioma: Disclosed are compounds for the treatment of cancer. Compounds disclosed herein are particularly effective for the selective inhibition of glioma cells.... Agent: University Of Tennessee Research Foundation

20140296287 - Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds: s

20140296288 - Imino-sugar c-glycosides, preparation and use thereof: The present disclosure relates to iminosugar derivatives and processes for the preparation thereof. The disclosed compounds have glycosidase inhibiting properties, and are useful in the treatment of various diseases, such as type 2 diabetes, neurodegenerative diseases or lysosomal storage disorders. The present disclosure also relates to pharmaceutical compositions containing the... Agent: Centre National De La Recherche Scientifique

20140296289 - Thiazolyl oxime ethers and hydrazones as crop protection agents: in which the symbols A, L1, L2, Y, W, X, R1, R2, R3, R4, R5, R6 and R7 have the meanings given in the description, and also agrochemically active salts thereof, and their use for controlling phytopathogenic harmful fungi, and also methods for controlling phytopathogenic harmful fungi and processes for... Agent: Bayer Cropscience Ag

20140296290 - Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter: Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and therapeutically acceptable salts thereof are provided.... Agent:

20140296292 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.... Agent:

20140296291 - Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: The invention relates to novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel... Agent:

20140296293 - Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat: The present invention relates to compositions comprising a lipophilic local anaesthetic, preferably bupivacaine or a pharmaceutically active salt thereof, which are formulated for local administration to the mouth or throat of a subject. The compositions are useful in the treatment or alleviation of pain, burning or xerostomia of the oral... Agent: Oracain Ii Aps

20140296294 - Novel cannabinoid receptor 2 (cb2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy,... Agent:

20140296295 - 2-alkoxy-substituted dicyanopyridines and their use: The present application relates to novel 2-alkoxy-substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.... Agent:

20140296296 - Biaryl-propionic acid derivatives and their use as pharmaceuticals: wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal... Agent:

20140296298 - Composition and method for controlling harmful arthropods: The present invention provides a composition for controlling harmful arthropods having an excellent controlling harmful arthropods comprising an amide represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at least one kind of pyrazole compounds selected from the... Agent: Sumitomo Chemical Company, Limited

20140296297 - Materials having embedded insecticides and additives: The present invention concerns polymeric material containing at least an embedded insecticidally active ingredient and an additive, which are released at room temperature. It similarly concerns materials produced from this polymer, for example in the form of self-supporting film/sheet, threads, wovens, fabrics, textiles, nets, curtains and pellets. The invention further... Agent:

20140296299 - Methods and compositions for locally increasing body fat: Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a composition comprising a pharmaceutically acceptable carrier,... Agent: Topokine Therapeutics, Inc.

20140296300 - Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis: The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In... Agent: Cell Therapy And Technology S.a. De C.v.

20140296301 - Topical ophthalmological pharmaceutical composition containing regoragenib: The present invention relates to topical ophthalmological pharmaceutical compositions containing regorafenib, a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating ophthalmological disorders.... Agent: Bayer Intellectual Property Gmbh

20140296302 - Methods for treating inflammation: The present invention provides methods for treating or limiting development of inflammatory disorders.... Agent:

20140296303 - Use of pyridoxamine to treat and/or prevent disease processes: Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of... Agent:

20140296304 - Pharmaceutically active disubstituted pyridine derivatives: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical... Agent: Bayer Intellectual Property Gmbh

20140296305 - Use of quaternary pyridinium salts as vasoprotective agents: wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if... Agent: Pharmena S.a.

20140296306 - Amide compound and medicinal use thereof: e

20140296308 - Drugs for inhibiting p38 and uses thereof: The present invention relates to compounds with a benzoxadiazolyl amine structure which are capable of inhibiting the activation or the biological activity of p38 mitogen-activated protein kinase (MAPK) and the use thereof in the treatment of a disease that can be alleviated by means of inhibiting the activation or the... Agent:

20140296307 - Potent analogues of the c-myc inhibitor 10074-g5 with improved cell permeability: The present invention relates compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a... Agent: University Of Maryland, Baltimore

20140296309 - Modified release compositions of epalrestat or a derivative thereof and methods for using the same: Modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided.... Agent: Bionevia Pharmaceuticals Inc.

20140296310 - Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives: Methods of treating, preventing and ameliorating bacteria! infections with 1,2-benzisothiazolinone and isoindolinone derivatives are disclosed. Pharmaceutical compositions containing 1,2-benzisothiazolinone and isoindolinone derivatives are useful for treating bacteria! infections caused by drug resistant strains of bacteria, including but not limited to methicillin and vancomycin bacterial organisms.... Agent: Georgetown University

20140296311 - Gamma secretase modulators: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) and use of the compounds in the treatment of neurodegenerative diseases... Agent:

20140296312 - Treatment of breast cancer: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V,... Agent: Medivation Prostate Therapeutics, Inc.

20140296313 - (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators: e

20140296314 - Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine: Effective treatments of dystonia and/or post-stroke spasticity for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve dystonia and/or post-stroke spasticity caused by diverse sources. When appropriate formulations are provided within biodegradable polymers, this relief... Agent: Warsaw Orthopedic, Inc.

20140296316 - Hydrate and crystal of fluorene compounds: f

20140296315 - Pyrazole-amide compounds and pharmaceutical use thereof:

20140296317 - 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity: The invention relates to the 5S,4R-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with cognition enhancing activity of high pharmacological value and to its preparation method which includes the synthesis of 5S-methyl-4R-phenylpyrrolidin-2-one, its N-alkylation with ethyl haloacetate and the treatment of intermediate ethyl 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetate with ammonia.... Agent:

20140296328 - High concentration olopatadine ophthalmic composition: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase... Agent:

20140296329 - Phytoestrogen product of red clover and pharmaceutical uses thereof: The present invention provides compositions comprising optimized ratios of Red clover phytoestrogens as determined by a proprietary physiologically based pharmacokinetic and pharmacodynamic model. The compositions are useful for modulating bone remodeling, and prevention and treatment of osteoporosis.... Agent:

20140296330 - Treatment of circadian rhythm disorders: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.... Agent:

20140296331 - Treatment of circadian rhythm disorders: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.... Agent:

20140296332 - Treatment of circadian rhythm disorders: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.... Agent:

20140296333 - Composition of the treatment of vascular diseases or kca3.1 channel-mediated diseases comprising modafinil or derivatives thereof: The present invention relates to modafinil or derivatives thereof as a medicine for the treatment of vascular diseases or KCa3.1 channel (Ca activated K channel) mediated diseases and a novel use of the same. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of... Agent: Ewha University-industry Collaboration Foundation

20140296334 - N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.... Agent:

20140296335 - Short acting phenylalkylamine calcium channel blockers and uses thereof: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle... Agent:

20140296336 - Solid retard formulations based on solid dispersions: A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.... Agent: Abbott Gmbh & Co. Kg

20140296337 - Cns modulators: A method is provided for treating a subject in need of therapy for depression, anxiety, impaired cognition and/or pain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide anti-depressant effect, cognition enhancing and/or analgesic effect. Preferred materials... Agent:

20140296338 - Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes: An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and/or therapeutic agent for cardiovascular... Agent:

20140296339 - Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent:

20140296340 - Combination/association of adapalene and benxoyl peroxide for treating acne lesions: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).... Agent:

20140296341 - Formulations based on solid dispersions: The present invention relates to formulations comprising a solid dispersion product of an active agent having at least one of a hydrogen bond donor moiety (e.g. ibuprofen, fenofibric acid or naproxen) and a proton donor moiety and a pharmaceutically acceptable polyvinyllactam polyvinylacetate poly(alkylene glycol) graft copolymer, and to methods for... Agent:

20140296342 - Pharmaceutical formulation comprising nsaid and cyclodextrin: The present invention provides a liquid composition in comprising an aqueous solution of an NSAID and one or more cyclodextrins.... Agent: Reckitt Benckiser Healthcare International Limited

20140296343 - Non-peptide bdnf neurotrophin mimetics: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.... Agent:

20140296344 - Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.... Agent:

20140296345 - Method of enhancing hair growth: wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is... Agent:

20140296346 - Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride: A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.... Agent:

20140296347 - Method of treating onychomycosis: The present invention is directed to a nail lacquer consisting essentially of terbinafine as an antimycotic agent, hydroxypropyl chitosan as film forming agent, water and a lower alkanol as solvents. The invention is also directed to a method for treating onychomycosis by topically administering such a nail lacquer to a... Agent: Polichem Sa

20140296348 - Ophthalmological aqueous composition: The present invention provides an aqueous ophthalmic composition having a pH of 7 or more, containing a terpenoid and zinc chloride. According to the present invention, an aqueous ophthalmic composition is provided in which adsorption of the terpenoid to a container can be inhibited, thereby making it possible to inhibit... Agent:

20140296349 - Antimicrobial cleaning composition: The present invention relates to an antimicrobial cleaning composition comprising at least one sugar surfactant and a compound of the formula (I) as biocide, and to the use of the sugar surfactants for improving the activity of the biocide.... Agent: Basf Se

20140296350 - Method for the formulation of hand sanitizer: A hand sanitizer composition that provides effective skin sanitization and exhibits low flammability, while containing sufficient humectant for moisturization of the skin includes an alcohol selected from the group consisting of alcohol(s) containing 4 to 6 carbon atoms in an amount of from about 10% to about 60% by volume,... Agent: Working Bugs, LLC

20140296351 - Pharmaceutical formulation: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein... Agent: Gw Pharma Limited

20140296352 - Compositions containing a polymer with a carbosiloxane dendrimer unit and a large amount of monoalcohol: This invention relates to a composition containing a physiologically acceptable medium containing at least one vinyl polymer having at least one carbosiloxane dendrimer-derived unit and one or more monoalcohol(s) containing 2 to 8 carbon atoms, in which the amount of monoalcohol(s) is between 10% and 40% by weight with respect... Agent: L'oreal

20140296353 - Prion free nanoparticle compositions and methods of making thereof: The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also... Agent: Abraxis Bioscience, LLC

20140296354 - Synthesis of peptoid-based small molecular gelators from multiple component reactions: Described herein are the one-pot synthesis and characterization of a library of low molecular weight peptoid compounds that are able to form gels at room temperature. The compounds are synthesized from biologically-based starting materials, are biocompatible, and are resistant to degradation by proteases and peptidases. The compounds and gels synthesized... Agent: Old Dominion University Research Foundation

20140296355 - Unbiased dna methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and... Agent: Wisconsin Alumni Research Foundation

  
  
  
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.08207 seconds

PATENT INFO